You are here: Home » News-CM » Equities » Hot Pursuit
Business Standard

Suven Life Sciences gains after securing two product patents

Capital Market 

rose 2.50% to Rs 199 at 11:00 on after the company said it secured two product patents in and Israel.

The announcement was made during trading hours today, 18 October 2016.

Meanwhile, the Sensex was up 208.06 points, or 0.76%, to 27,738.03.

On BSE, so far 40,000 shares were traded in the counter, compared with average daily volume of 76,255 shares in the past one quarter. The stock hit a high of Rs 204.30 and a low of Rs 195 so far during the day. The stock hit a 52-week high of Rs 293.95 on 23 October 2015. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had outperformed the market over the past 30 days till 17 October 2016, rising 2.29% compared with 3.74% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 2.17% as against Sensex's 0.93% decline.

The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.

(Suven) announced that the grant of one (1) product patent from and one (1) product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia, the company said in a statement.

With these new patents, Suven has a total of twenty three (23) granted patents from and twelve (12) granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.

Suven Life Sciences' net profit rose 58.2% to Rs 32.58 crore on 31.7% rise in net sales to Rs 133.23 crore in Q1 June 2016 over Q1 June 2015.

is a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders and contract research and manufacturing services (CRAMS).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Suven Life Sciences gains after securing two product patents

Suven Life Sciences rose 2.50% to Rs 199 at 11:00 IST on BSE after the company said it secured two product patents in Europe and Israel.

rose 2.50% to Rs 199 at 11:00 on after the company said it secured two product patents in and Israel.

The announcement was made during trading hours today, 18 October 2016.

Meanwhile, the Sensex was up 208.06 points, or 0.76%, to 27,738.03.

On BSE, so far 40,000 shares were traded in the counter, compared with average daily volume of 76,255 shares in the past one quarter. The stock hit a high of Rs 204.30 and a low of Rs 195 so far during the day. The stock hit a 52-week high of Rs 293.95 on 23 October 2015. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had outperformed the market over the past 30 days till 17 October 2016, rising 2.29% compared with 3.74% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 2.17% as against Sensex's 0.93% decline.

The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.

(Suven) announced that the grant of one (1) product patent from and one (1) product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia, the company said in a statement.

With these new patents, Suven has a total of twenty three (23) granted patents from and twelve (12) granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.

Suven Life Sciences' net profit rose 58.2% to Rs 32.58 crore on 31.7% rise in net sales to Rs 133.23 crore in Q1 June 2016 over Q1 June 2015.

is a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders and contract research and manufacturing services (CRAMS).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Suven Life Sciences gains after securing two product patents

rose 2.50% to Rs 199 at 11:00 on after the company said it secured two product patents in and Israel.

The announcement was made during trading hours today, 18 October 2016.

Meanwhile, the Sensex was up 208.06 points, or 0.76%, to 27,738.03.

On BSE, so far 40,000 shares were traded in the counter, compared with average daily volume of 76,255 shares in the past one quarter. The stock hit a high of Rs 204.30 and a low of Rs 195 so far during the day. The stock hit a 52-week high of Rs 293.95 on 23 October 2015. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had outperformed the market over the past 30 days till 17 October 2016, rising 2.29% compared with 3.74% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 2.17% as against Sensex's 0.93% decline.

The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.

(Suven) announced that the grant of one (1) product patent from and one (1) product patent from corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia, the company said in a statement.

With these new patents, Suven has a total of twenty three (23) granted patents from and twelve (12) granted patents from Israel. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, the company said.

Suven Life Sciences' net profit rose 58.2% to Rs 32.58 crore on 31.7% rise in net sales to Rs 133.23 crore in Q1 June 2016 over Q1 June 2015.

is a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders and contract research and manufacturing services (CRAMS).

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard